Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2381012
Max Phase: Preclinical
Molecular Formula: C19H23ClN2O3
Molecular Weight: 362.86
Molecule Type: Small molecule
Associated Items:
ID: ALA2381012
Max Phase: Preclinical
Molecular Formula: C19H23ClN2O3
Molecular Weight: 362.86
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CCC[C@H]1N1C(=O)CC(=O)N(CCc2cccc(Cl)c2)C1=O
Standard InChI: InChI=1S/C19H23ClN2O3/c1-19(2)9-4-7-15(19)22-17(24)12-16(23)21(18(22)25)10-8-13-5-3-6-14(20)11-13/h3,5-6,11,15H,4,7-10,12H2,1-2H3/t15-/m1/s1
Standard InChI Key: MTWKHJUQYFVCHB-OAHLLOKOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 362.86 | Molecular Weight (Monoisotopic): 362.1397 | AlogP: 3.64 | #Rotatable Bonds: 4 |
Polar Surface Area: 57.69 | Molecular Species: ACID | HBA: 3 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 5.00 | CX Basic pKa: | CX LogP: 3.89 | CX LogD: 1.56 |
Aromatic Rings: 1 | Heavy Atoms: 25 | QED Weighted: 0.77 | Np Likeness Score: -0.37 |
1. Kang S, Cooper G, Dunne SF, Luan CH, Surmeier DJ, Silverman RB.. (2013) Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease., 56 (11): [PMID:23651412] [10.1021/jm4005048] |
Source(1):